title: Adherence to targeted oral anticancer medications.
abstract: The use of targeted oral anticancer medications (OAMs) is becoming increasingly prevalent in cancer care. Approximately 25-30% of the oncology drug pipeline involves oral agents and there are now over 50 OAMs approved by the Food and Drug Administration. This change represents a major shift in management of patients with cancer from directly observed, intermittent intravenous therapy to self-administered, oral chronic therapy. The increased prevalence of OAMs raises the issue of adherence in oncology, including understanding the challenges of adherence to OAMs. This review focuses on studies of adherence for patients taking molecularly targeted OAMs for breast cancer, chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). We then discuss barriers to adherence and studies performed to date testing interventions for improving adherence. Finally, we discuss future areas of investigation needed to define and improve adherence to OAMs in targeted therapy for cancer.
authors: Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, 5841 S. Maryland Ave., Chicago, Illinois 60637, USA.
authors: Daniel M
authors: DM
authors: Geynisman
authors: Karen E
authors: KE
authors: Wickersham
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006297:Health Services Accessibility; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D055118:Medication Adherence; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
references: Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S19-27
references: 22821550
references: Clin Transl Oncol. 2013 May;15(5):343-57
references: 23359171
references: BMJ. 2009 Oct 29;339:b4220
references: 19875426
references: Oncol Nurs Forum. 2012 Jul;39(4):E373-9
references: 22750908
references: J Clin Oncol. 1997 Jan;15(1):110-5
references: 8996131
references: Leuk Res. 2012 Jul;36(7):817-25
references: 22364811
references: Leuk Res. 2011 May;35(5):626-30
references: 21095002
references: J Clin Oncol. 2009 Jul 1;27(19):3141-7
references: 19451435
references: Curr Med Res Opin. 2012 Feb;28(2):213-9
references: 22168217
references: Pharmacoeconomics. 2011 Apr;29(4):315-29
references: 21395351
references: Nurs Res. 2009 Nov-Dec;58(6):410-8
references: 19851122
references: Med Care. 2004 Mar;42(3):200-9
references: 15076819
references: Semin Oncol Nurs. 2011 May;27(2):116-32
references: 21514481
references: Oncology (Williston Park). 2012 Mar;26(3):290-301
references: 22545314
references: Eur J Cancer Care (Engl). 2012 Jan;21(1):10-9
references: 22004071
references: J Clin Oncol. 2012 Feb 10;30(5):482-7
references: 22231040
references: J Clin Oncol. 2003 Feb 15;21(4):602-6
references: 12586795
references: Expert Rev Anticancer Ther. 2011 Jul;11(7):991-7
references: 21806322
references: J Clin Oncol. 1993 Jun;11(6):1189-97
references: 8501505
references: AIDS. 2010 Jan 28;24(3):395-403
references: 20099399
references: Am J Hematol. 2012 Jul;87(7):687-91
references: 22473898
references: Clin J Oncol Nurs. 2007 Dec;11(6):793-6
references: 18063536
references: Br J Cancer. 2012 Oct 9;107(8):1249-56
references: 22955858
references: Med Care. 2005 Jun;43(6):521-30
references: 15908846
references: Chest. 2006 Jul;130(1 Suppl):65S-72S
references: 16840369
references: Eur J Cancer. 2012 Apr;48(6):912-20
references: 22033327
references: Curr Med Res Opin. 2012 Jul;28(7):1155-62
references: 22738777
references: Ann Intern Med. 2009 Nov 17;151(10):687-95
references: 19920269
references: Am J Hematol. 2011 Jun;86(6):471-4
references: 21538468
references: Lancet Oncol. 2010 Oct;11(10):942-9
references: 20864406
references: Oncology (Williston Park). 2012 Mar;26(3):304, 306
references: 22545316
references: Anticancer Res. 2011 Apr;31(4):1407-9
references: 21508393
references: Cancer Nurs. 2013 Jan-Feb;36(1):18-28
references: 23235499
references: BMC Cancer. 2011 Jul 01;11:284
references: 21722354
references: J Clin Oncol. 2010 Sep 20;28(27):4120-8
references: 20585090
references: Pharmacoeconomics. 2007;25(6):481-96
references: 17523753
references: Cancer Treat Rev. 2011 Jun;37(4):291-9
references: 21078547
references: J Clin Oncol. 2004 Aug 15;22(16):3309-15
references: 15310774
references: Breast Cancer Res Treat. 2006 Sep;99(2):215-20
references: 16541307
references: Oncology (Williston Park). 2013 Jan;27(1):38-44, 46, 48 passim
references: 23461041
references: Blood. 2011 Apr 7;117(14):3733-6
references: 21346253
references: Blood. 2009 May 28;113(22):5401-11
references: 19349618
references: Value Health. 2008 Jan-Feb;11(1):44-7
references: 18237359
references: Patient Prefer Adherence. 2011;5:307-14
references: 21792302
references: J Hematol Oncol. 2010 Nov 26;3:47
references: 21108851
references: J Pharm Technol. 2014 Feb;30(1):21-30
references: 34860884
references: Expert Opin Drug Saf. 2012 May;11 Suppl 1:S49-59
references: 22149481
references: J Oncol Pharm Pract. 2012 Sep;18(3):379-80
references: 22801957
references: J Natl Compr Canc Netw. 2008 Mar;6 Suppl 3:S1-14
references: 18377852
references: Curr Med Res Opin. 2010 Jan;26(1):61-9
references: 19905880
references: CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66
references: 19147869
references: Oncologist. 2012;17(4):536-42
references: 22477724
references: Crit Rev Oncol Hematol. 2012 Oct;84(1):93-100
references: 22280914
references: Clin Pharmacol Ther. 2013 Mar;93(3):242-4
references: 23340477
references: J Natl Cancer Inst. 2002 May 1;94(9):652-61
references: 11983753
references: J Clin Oncol. 2008 Feb 1;26(4):556-62
references: 18180462
references: Patient Prefer Adherence. 2012;6:253-62
references: 22536061
references: J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):529-36
references: 19223785
references: N Engl J Med. 2005 Aug 4;353(5):487-97
references: 16079372
references: Clin Lung Cancer. 2013 Jul;14(4):390-8
references: 23313173
references: J Clin Oncol. 2010 May 10;28(14):2381-8
references: 20385986
references: Am J Hematol. 2012 Nov;87(11):1037-45
references: 23090888
references: Eur Urol. 2012 Feb;61(2):307-16
references: 22055147